论文部分内容阅读
在６２例慢性乙型肝炎（乙肝）患者中，３８例（治疗组）接受重组α－２ｂ干扰素治疗，２４例（对照组）接受抗乙肝免疫核糖核醚治疗。结果表明，治疗组ＨＢｅＡｇ和ＨＢＶＤＮＡ清除率明显高于对照组（Ｐ＜０．０５），血清ＡＬＴ水平明显升高的患者（ＡＬＴ＞７０Ｕ）及慢性活动型肝炎患者对干扰素的治疗反应明显优于ＡＬＴ正常及慢性迁延型肝炎病人（Ｐ＜０．０５）。
Of the 62 patients with chronic hepatitis B (hepatitis B), 38 (treatment group) received recombinant interferon alpha-2b and 24 (control group) received anti-hepatitis B immunosuppressive therapy. The results showed that the treatment group HBeAg and HBVDNA clearance rate was significantly higher than the control group (P lt; 0.05), serum ALT levels significantly elevated patients (ALT> 70U) and chronic active hepatitis patients response to interferon was significantly better In ALT patients with normal and chronic persistent hepatitis (P <0.05).